INTELLANCE-2: ABT-414 Alone or ABT-414 Plus Temozolomide Versus Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase 2 Study of the EORTC Brain Tumor Group

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Apr 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Depatuxizumab mafodotin (Primary) ; Lomustine; Temozolomide
Indications Anaplastic astrocytoma; Diffuse intrinsic pontine glioma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Acronyms INTELLANCE 2
Sponsors AbbVie; AbbVie Germany

15 Feb 2021 Results of a pre-specified exploratory analysis assessing the health-related quality of life (HRQoL) and neurological deterioration-free survival (NDFS), published in the European Journal of Cancer
23 May 2020 This trial is completed in Poland (Global End Date: 24 Jun 2019), according to European Clinical Trials Database record.
08 May 2020 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com